Headquartered in Durham, NC, Tergus Pharma is a full-service CRO for topical pharmaceutical research & development, testing and cGMP manufacturing. They offer expertise in formulation development of topical formulations, and knowledge of the regulatory landscape to the unique capability of Proof of Concept (PoC) studies such as Skin Permeation / In Vitro Permeation Test (IVPT), In Vitro Release Test (IVRT), and Clinical Supplies Manufacturing (Phase I, II and III Batches).
EnDev’s expertise expands the company’s capabilities for dermatological R&D, and skin biology research including skin irritation, skin sensitization, and drug activity testing using healthy or genetically-modified In Vitro and/or in Ex Vivo human skin models. The EnDev team also adds experience and knowledge in early safety screenings, drug delivery and early drug metabolism and pharmacokinetic (DMPK) studies, product development, manufacturing support, and consulting services.
EnDev’s location on the NCRC allows them to leverage the advanced scientific capabilities of the David H Murdock Research Institute (DHMRI) and UNC Charlotte Bioinformatics to provide best in class dermatological pharmaceutical development.
Tergus and Endev align with their partners to deliver products to market faster.